Treatment with anti-vegf antibodies
AssigneeGenentech, Inc.
InventorsGwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny
Life of this patent
Estimating the term…
Abstract
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
Claims8
A kit for treating metastatic colorectal cancer in a human patient comprising a package comprising an anti-VEGF antibody composition and instructions for using the anti-VEGF antibody composition in combination with IFL (irinotecan, 5-fluorouracil and leucovorin), wherein the instructions further comprise FIG. 1.
A kit for treating metastatic colorectal cancer in a human patient comprising a package comprising an anti-VEGF antibody composition and instructions for using the anti-VEGF antibody composition in combination with IFL, wherein the instructions recite that the medium survival for patients receiving IFL and bevacizumab is 20.3 months with a hazard ratio of 0.66.
A kit for treating metastatic colorectal cancer in a human patient comprising a package comprising an anti-VEGF antibody composition and instructions for using the anti-VEGF antibody composition in combination with IFL, wherein the instructions recite that the progression free survival for patients receiving IFL and bevacizumab is 10.6 months with a hazard ratio of 0.54.
A kit for treating metastatic colorectal cancer in a human patient comprising a package comprising an anti-VEGF antibody composition and instructions for using the anti-VEGF antibody composition in combination with IFL, wherein the instructions recite that the median duration of response for patients receiving IFL and bevacizumab is 10.4 months.
A kit for treating a cancer patient comprising a package comprising an anti-VEGF antibody composition and instructions for using the anti-VEGF antibody in combination with at least one chemotherapeutic agent, wherein the instructions provide information about the risk of gastrointestinal perforation during treatment with the anti-VEGF antibody composition.
Dependencies are inferred from the claim text.